Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer

被引：40

作者：

Ranson, MR

Cheeseman, S

White, S

Margison, J

机构：

[1] Christie Hosp NHS Trust, Canc Res Campaign, Dept Med Oncol, Manchester M20 4BX, Lancs, England

[2] Christie Hosp NHS Trust, Dept Clin Pharmacol, Manchester M20 4BX, Lancs, England

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2001年 / 37卷 / 02期

关键词：

Caelyx; Doxil; doxorubicin; liposome; breast cancer;

D O I：

10.1016/S1040-8428(00)00107-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anthracyclines are amongst the most active drugs in the treatment of breast cancer. Stealth liposomal doxorubicin (Caelyx, Doxil, Alza Pharmaceuticals Inc.) is a promising new agent under investigation for the treatment of breast cancer and other solid tumours. The liposomal encapsulation alters drug pharmacokinetics and leads to a marked change in toxicity profile compared to non-liposomal doxorubicin. The results of recently completed and ongoing clinical trials in breast cancer are reviewed. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

引用

收藏

页码：115 / 120

页数：6

相关论文

共 52 条

[1] DIFFUSION OF UNIVALENT IONS ACROSS LAMELLAE OF SWOLLEN PHOSPHOLIPIDS [J].

BANGHAM, AD ;

STANDISH, MM ;

WATKINS, JC .

JOURNAL OF MOLECULAR BIOLOGY, 1965, 13 (01) :238-+

[2] The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin [J].

Berry, G ;

Billingham, M ;

Alderman, E ;

Richardson, P ;

Torti, F ;

Lum, B ;

Patek, A ;

Martin, FJ .

ANNALS OF ONCOLOGY, 1998, 9 (07) :711-716

[3] THE USE OF GRANULOCYTE COLONY-STIMULATING FACTOR TO INCREASE THE INTENSITY OF TREATMENT WITH DOXORUBICIN IN PATIENTS WITH ADVANCED BREAST AND OVARIAN-CANCER [J].

BRONCHUD, MH ;

HOWELL, A ;

CROWTHER, D ;

HOPWOOD, P ;

SOUZA, L ;

DEXTER, TM .

BRITISH JOURNAL OF CANCER, 1989, 60 (01) :121-125

[4] A COMPARISON OF 2 DOSES OF ADRIAMYCIN IN THE PRIMARY CHEMOTHERAPY OF DISSEMINATED BREAST-CARCINOMA [J].

CARMOPEREIRA, J ;

COSTA, FO ;

HENRIQUES, E ;

GODINHO, F ;

CANTINHOLOPES, MG ;

SALESLUIS, A ;

RUBENS, RD .

BRITISH JOURNAL OF CANCER, 1987, 56 (04) :471-473

[5] Polyethylene glycol-liposomal doxorubicin - A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma [J].

Coukell, AJ ;

Spencer, CM .

DRUGS, 1997, 53 (03) :520-538

[6] A RANDOMIZED TRIAL OF DOXORUBICIN, MITOXANTRONE AND BISANTRENE IN ADVANCED BREAST-CANCER (A SOUTH-WEST-ONCOLOGY-GROUP STUDY) [J].

COWAN, JD ;

OSBORNE, CK ;

NEIDHART, JA ;

VONHOFF, DD ;

CONSTANZI, JJ ;

VAUGHN, CB .

INVESTIGATIONAL NEW DRUGS, 1985, 3 (02) :149-152

[7] PROTRACTED DRUG INFUSIONS IN CANCER-TREATMENT - AN APPRAISAL OF 5-FLUOROURACIL, DOXORUBICIN, AND PLATINUMS [J].

DELAFLORWEISS, E ;

UZIELY, B ;

MUGGIA, FM .

ANNALS OF ONCOLOGY, 1993, 4 (09) :723-733

[8] USE OF ANIONIC LIPOSOMES FOR THE REDUCTION OF CHRONIC DOXORUBICIN-INDUCED CARDIOTOXICITY [J].

FORSSEN, EA ;

TOKES, ZA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (03) :1873-1877

[9]

GABIZON A, 1994, CANCER RES, V54, P987

[10] Liposome longevity and stability in circulation: Effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines [J].

Gabizon, A ;

Chemla, M ;

Tzemach, D ;

Horowitz, AT ;

Goren, D .

JOURNAL OF DRUG TARGETING, 1996, 3 (05) :391-398

← 1 2 3 4 5 6 →